| 1 |
Cirrhotic liver response to the ...
|
Rattus norvegicus
|
Rattus norvegicus |
| Cell |
Liver |
| Perturbation |
Sunitinib |
| Disease |
Cirrhosis |
|
| 2 |
Expression data from breast cancer tumors ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Tumor |
| Perturbation |
Sunitinib |
| Disease |
Breast cancer |
|
| 3 |
Sunitinib treatment exacerbates intratumoral ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Kidney |
| Perturbation |
Sunitinib |
| Disease |
Renal cancer |
|
| 4 |
Gene expression profiles of Sunitinib-treated ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BTIC (brain tumor ... |
| Perturbation |
Sunitinib |
| Concentration |
1uM |
|
| 5 |
Effect of Sunitinib treatment withdrawal on ...
|
Mus musculus
|
Mus musculus |
| Cell |
MDAMB231 tumors |
| Perturbation |
Sunitinib |
| Concentration |
40mg/kg/day |
|
| 6 |
Analysis of Gene Expression of Human Renal ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Renal cell tumor |
| Perturbation |
Sunitinib |
| Relevant information |
Surgery Vs. ... |
|
| 7 |
Differentiation of Mammary Tumors by SKI-606 ...
|
Mus musculus
|
Mus musculus |
| Cell |
Mammary ... |
| Perturbation |
Bostutinib |
| Concentration |
100 mg/kg |
|
| 8 |
Global gene expression changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
K562 |
| Perturbation |
Dasatinib |
| Time |
4hrs |
| Concentration |
100nM |
|
| 9 |
Global gene expression changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
K562 |
| Perturbation |
Dasatinib |
| Time |
8hrs |
| Concentration |
100nM |
|
| 10 |
Global gene expression changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
K562 |
| Perturbation |
Dasatinib |
| Time |
24hrs |
| Concentration |
100nM |
|
| 11 |
Fasting potentiates the anticancer activity of ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Lung (H3122 non small ... |
| Perturbation |
Crizotinib |
| Time |
72hrs |
| Concentration |
400nM |
|
| 12 |
Improved antitumor activity of immunotherapy ...
|
Mus musculus
|
Mus musculus |
| Cell |
SM1 tumor |
| Perturbation |
Dabratinib |
|
| 13 |
Spectrum, clinical correlates and clinical ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Melanoma tumor |
| Perturbation |
Dabrafenib |
| Disease |
Melanoma |
|
| 14 |
Anti-proliferative effects of continued ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMel28 |
| Perturbation |
Dabrafenib |
| Time |
24hrs |
| Concentration |
100nM |
|
| 15 |
Anti-proliferative effects of continued ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMel28 |
| Perturbation |
Trametinib |
| Time |
24hrs |
| Concentration |
10nM |
|
| 16 |
Spectrum, clinical correlates and clinical ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BRAF V600E |
| Perturbation |
Vemurafenib |
| Disease |
Melanoma |
|
| 17 |
Braf inhibitors reverse the unique molecular ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BRAF-V600E |
| Perturbation |
Vemurafenib |
| Time |
48hrs |
| Concentration |
1000nM |
|
| 18 |
Gene expression profiling of HDLM-2 Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HDLM2 |
| Perturbation |
Sorafenib |
| Time |
24hrs |
| Concentration |
5uM |
| Disease |
Hodgkin lymphoma |
|
| 19 |
Gene expression profiling of L-540 Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
L540 |
| Perturbation |
Sorafenib |
| Time |
24hrs |
| Concentration |
5uM |
| Disease |
Hodgkin lymphoma |
|
| 20 |
Gene expression profiling of HD-MyZ Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HDMyZ |
| Perturbation |
Sorafenib |
| Time |
24hrs |
| Concentration |
5uM |
| Disease |
Hodgkin lymphoma |
|
| 21 |
Gene expression analysis of Hodgkin lymphoma ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HDLM2 |
| Perturbation |
Sorafenib |
| Time |
5uM |
| Concentration |
24hrs |
| Disease |
Hodgkin lymphoma |
|
| 22 |
Sorafenib treatment of FLT3-ITD+ acute myeloid ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
CD33+CD34+ myeloblast |
| Perturbation |
Sorafenib |
| Time |
Twice daily |
| Concentration |
200-400mg |
| Disease |
AML |
|
| 23 |
Expression in irradiated MEFs exposed to ...
|
Mus musculus
|
Mus musculus |
| Cell |
MEFs (irradiated) |
| Perturbation |
Nilotinib |
| Concentration |
16nM |
|
| 24 |
Imatinib and Nilotinib induced molecular ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
K562 |
| Perturbation |
Nilotinib |
| Concentration |
0.05uM |
| Disease |
CML |
|
| 25 |
Gene expression analysis in EGFR-mutant NSCLC ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
PC9 |
| Perturbation |
Erlotinib |
| Concentration |
2uM |
|
| 26 |
Gene expression analysis in EGFR-mutant NSCLC ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC827 |
| Perturbation |
Erlotinib |
| Concentration |
2uM |
|
| 27 |
Whole transcriptome analysis of erlotinib ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC827 |
| Perturbation |
Erlotini |
| Time |
6hrs |
|
| 28 |
Genome-wide analysis of EGFR inhibitor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SQ20B |
| Perturbation |
Erlotinib |
| Time |
48hrs |
| Concentration |
5uM |
|
| 29 |
Genome-wide analysis of EGFR inhibitor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
FADU |
| Perturbation |
Erlotinib |
| Time |
48hrs |
| Concentration |
5uM |
|
| 30 |
Expression data from EGFR WT or EGFR mutant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC78 |
| Perturbation |
Erlotinib |
| Time |
24hrs |
| Concentration |
1mM |
|
| 31 |
Genome-wide analysis of EGFR inhibitor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Cal 27 |
| Perturbation |
Erlotinib |
| Time |
48hrs |
| Concentration |
5uM |
|
| 32 |
Microarray study to understand acquired ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC827 |
| Perturbation |
Erlotinib |
| Time |
12hrs |
|
| 33 |
Dynamic re-wiring of apoptotic signaling ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BT20 |
| Perturbation |
Erlotinib |
| Time |
0.5hrs |
| Concentration |
10uM |
|
| 34 |
Dynamic re-wiring of apoptotic signaling ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BT20 |
| Perturbation |
Erlotinib |
| Time |
1 day |
| Concentration |
10uM |
|
| 35 |
Targeting FAK and EGFR/HER-2 with small ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKBR3 |
| Perturbation |
Lapatinib |
| Concentration |
5uM |
|
| 36 |
Systems analysis of adaptive responses to MAP ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
DM331 |
| Perturbation |
Lapatinib |
| Time |
8hrs |
| Disease |
Melanoma |
|
| 37 |
Lapatinib effect on lapatinib-resistant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKBR3 |
| Perturbation |
Lapatinib |
| Concentration |
0.1uM |
| Relevant information |
Lapatinib sensitive |
|
| 38 |
Lapatinib effect on lapatinib-resistant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKBR3 |
| Perturbation |
Lapatinib |
| Concentration |
1uM |
| Relevant information |
Lapatinib sensitive |
|
| 39 |
Lapatinib-resistant HER2-positive breast tumor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BT474 |
| Perturbation |
Lapatinib |
| Concentration |
1uM |
|
| 40 |
Lapatinib-resistant HER2-positive breast tumor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BT474J4 |
| Perturbation |
Lapatinib |
| Concentration |
1uM |
|
| 41 |
Bone marrow microenvironment effect on ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Blood |
| Perturbation |
Imatinib |
| Concentration |
5uM |
|
| 42 |
Chronic myelogenous leukemia response to ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
CD34+ cells ... |
| Perturbation |
Imatinib |
| Disease |
CML |
|
| 43 |
Chronic myelogenous leukemia CD34+CD38- cells ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
CD34+CD38 cells |
| Perturbation |
Imatinib |
| Disease |
Chronic myelogenous ... |
|
| 44 |
Imatinib effects on chronic myelogenous ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
CD34+ cells |
| Perturbation |
Imatinib |
|
| 45 |
Imatinib induces mesenchymal stem ...
|
Mus musculus
|
Mus musculus |
| Cell |
MSCs |
| Perturbation |
Imatinib |
| Time |
96hrs |
|
| 46 |
Imatinib induces mesenchymal stem ...
|
Mus musculus
|
Mus musculus |
| Cell |
MSCs |
| Perturbation |
Imatinib |
| Time |
32hrs |
|
| 47 |
Imatinib induces mesenchymal stem ...
|
Mus musculus
|
Mus musculus |
| Cell |
MSCs |
| Perturbation |
Imatinib |
| Time |
64hrs |
|
| 48 |
An EphB-Abl signaling pathway important for ...
|
Mus musculus
|
Mus musculus |
| Cell |
Colon |
| Perturbation |
Imatinib |
| Time |
3hrs |
|
| 49 |
Combined inhibition of TGFβ and PDGF signaling ...
|
Mus musculus
|
Mus musculus |
| Cell |
Lung |
| Perturbation |
Imatinib |
|
| 50 |
An EphB-Abl signaling pathway important for ...
|
Mus musculus
|
Mus musculus |
| Cell |
Colon |
| Perturbation |
Imatinib |
| Time |
12hrs |
|
| 51 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC1143 |
| Perturbation |
Ruxolitinib |
| Time |
4hrs |
| Concentration |
1uM |
|
| 52 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC1143 |
| Perturbation |
Ruxolitinib |
| Time |
24hrs |
| Concentration |
1uM |
|
| 53 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SUM159PT |
| Perturbation |
Ruxolitinib |
| Time |
4hrs |
| Concentration |
1uM |
|
| 54 |
First ruxolitinib treatment of human alopecia ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Skin |
| Perturbation |
Ruxolitinib |
| Disease |
Alopecia |
|
| 55 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SUM159PT |
| Perturbation |
Ruxolitinib |
| Time |
24hrs |
| Concentration |
1uM |
|
| 56 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC38 |
| Perturbation |
Ruxolitinib |
| Time |
4hrs |
| Concentration |
1uM |
|
| 57 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC38 |
| Perturbation |
Ruxolitinib |
| Time |
24hrs |
| Concentration |
1uM |
|
| 58 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC70 |
| Perturbation |
Ruxolitinib |
| Time |
4hrs |
| Concentration |
1uM |
|
| 59 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC70 |
| Perturbation |
Ruxolitinib |
| Time |
24hrs |
| Concentration |
1uM |
|
| 60 |
Effect of ruxolitinib treatment on gene ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC70 |
| Perturbation |
Ruxolitinib |
| Time |
24hrs |
| Concentration |
1uM |
|
| 61 |
Capturing drug responses by quantitative ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
MCF7 |
| Perturbation |
Gefitinib |
| Time |
6hrs |
| Concentration |
1uM |
| Disease |
Breast cancer |
|
| 62 |
EGFR Isoforms and Gene Regulation in Human ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Hec50co |
| Perturbation |
Gefitinib |
| Time |
12hrs |
| Concentration |
1uM |
| Disease |
Endometrial ... |
|
| 63 |
EGFR Isoforms and Gene Regulation in Human ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Hec50co |
| Perturbation |
Gefitinib |
| Time |
24hrs |
| Concentration |
1uM |
| Disease |
Endometrial ... |
|
| 64 |
EGFR Isoforms and Gene Regulation in Human ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Ishikawa H |
| Perturbation |
Gefitinib |
| Time |
12hrs |
| Concentration |
1uM |
| Disease |
Endometrial ... |
|
| 65 |
EGFR Isoforms and Gene Regulation in Human ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Ishikawa H |
| Perturbation |
Gefitinib |
| Time |
24hrs |
| Concentration |
1uM |
| Disease |
Endometrial ... |
|
| 66 |
Establishment of Afatinib-Resistant Non-Small ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BR161 |
| Perturbation |
Afatinib |
| Time |
48hrs |
| Concentration |
10nM |
| Relevant information |
Resistant cell line |
|
| 67 |
Establishment of Afatinib-Resistant Non-Small ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BR161 |
| Perturbation |
Afatinib |
| Time |
48hrs |
| Concentration |
100nM |
| Relevant information |
Resistant cell line |
|
| 68 |
Establishment of Afatinib-Resistant Non-Small ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BR161 |
| Perturbation |
Afatinib |
| Time |
48hrs |
| Concentration |
1000nM |
| Relevant information |
Resistant cell line |
|
| 69 |
Prevention of Mouse AA with IL-15 pathway ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Tofacitinib |
| Disease |
13 weeks |
|
| 70 |
Prevention of Mouse AA with IL-15 pathway ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Ruxolitinib |
| Disease |
6 weeks |
|
| 71 |
Treatment of established mouse AA with topical ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Tofacitinib |
| Time |
6 weeks |
|
| 72 |
Treatment of established mouse AA with topical ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Tofacitinib |
| Time |
12 weeks |
|
| 73 |
Treatment of established mouse AA with topical ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Tofacitinib |
| Time |
24 weeks |
|
| 74 |
Gene expression in Vemurafenib-treated A375 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
A375 |
| Perturbation |
Vemurafenib |
| Concentration |
1uM |
| Disease |
Melanoma |
|
| 75 |
Gene expression in Vemurafenib-treated A375 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
A2058 |
| Perturbation |
Vemurafenib |
| Concentration |
1uM |
| Disease |
Melanoma |
|
| 76 |
Oncogenic BRAF harboring melanoma cell line ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
A375 |
| Perturbation |
Vemurafenib |
| Concentration |
10uM |
| Disease |
Melanoma |
|
| 77 |
Braf inhibitors reverse the unique molecular ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Peripheral blood |
| Perturbation |
Vemurafenib |
| Time |
48hrs |
| Concentration |
1000nM |
| Disease |
Hairy cell leukemia |
|
| 78 |
Braf inhibitors reverse the unique molecular ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Peripheral blood |
| Perturbation |
Vemurafenib |
| Time |
72hrs |
| Concentration |
1000nM |
| Disease |
Hairy cell leukemia |
|
| 79 |
Parent vs. Induced drug tolerant cells ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
WM164 |
| Perturbation |
Vemurafenib |
| Time |
16 days |
| Concentration |
500nM |
| Disease |
Melanoma |
|
| 80 |
Relief of feedback inhibition of HER3 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMEL28 |
| Perturbation |
Vemurafenib |
| Time |
1hr |
| Concentration |
2uM |
|
| 81 |
Relief of feedback inhibition of HER3 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMEL28 |
| Perturbation |
Vemurafenib |
| Time |
6hrs |
| Concentration |
2uM |
|
| 82 |
Relief of feedback inhibition of HER3 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMEL28 |
| Perturbation |
Vemurafenib |
| Time |
48hrs |
| Concentration |
2uM |
|
| 83 |
Relief of feedback inhibition of HER3 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SW1736 |
| Perturbation |
Vemurafenib |
| Time |
1hr |
| Concentration |
2uM |
|
| 84 |
Relief of feedback inhibition of HER3 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SW1736 |
| Perturbation |
Vemurafenib |
| Time |
6hrs |
| Concentration |
2uM |
|
| 85 |
Relief of feedback inhibition of HER3 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SW1736 |
| Perturbation |
Vemurafenib |
| Concentration |
2uM |
| Time |
48hrs |
|
| 86 |
Cirrhotic liver response to the ...
|
Rattus norvegicus
|
Rattus norvegicus |
| Cell |
Liver |
| Perturbation |
Sunitinib |
| Disease |
Cirrhosis |
|
| 87 |
Expression data from renal cancer xenograft ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
KURC1 |
| Perturbation |
Sunitinib |
| Concentration |
40mg/day |
| Relevant information |
Sunitinib resistant ... |
|
| 88 |
Gene expression changes during resistance ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
786O |
| Perturbation |
Sunitinib |
| Disease |
Renal cell carcinoma |
| Relevant information |
Sunitinib resistant ... |
|
| 89 |
Gene expression changes during resistance ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
A498 |
| Perturbation |
Sunitinib |
| Disease |
Renal cell carcinoma |
| Relevant information |
Sunitinib resistant ... |
|
| 90 |
GSE20921 Differentiation of Mammary Tumors by ...
|
Mus musculus
|
Mus musculus |
| Cell |
Mammary |
| Perturbation |
Bosutinib |
| Concentration |
100mg/kg |
|
| 91 |
Predominance of MAPK reactivation in early ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Skin (BRAF V600K) |
| Perturbation |
Dabrafenib |
| Disease |
Melanoma |
|
| 92 |
Gene expression profiling of HDLM-2 Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HDLM2 |
| Perturbation |
Sorafenib |
| Time |
24hrs |
| Concentration |
5uM |
|
| 93 |
Gene expression profiling of L-540 Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
L540 |
| Perturbation |
Sorafenib |
| Time |
24hrs |
| Concentration |
5uM |
|
| 94 |
GSE43053 - The multikinase inhibitor Sorafenib ...
|
Rattus norvergicus
|
Rattus norvergicus |
| Cell |
LCSC-2 |
| Perturbation |
Sorafenib |
| Disease |
Hepatocholangiocarcinoma |
|
| 95 |
Synthetic lethal screening with small molecule ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
VMM39 (mutant Ras) |
| Perturbation |
Sorafenib |
|
| 96 |
Lapatinib effect on lapatinib-resistant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKBR3R |
| Perturbation |
Lapatinib |
| Concentration |
0.1uM |
| Relevant information |
Lapatinib resistant |
|
| 97 |
Lapatinib effect on lapatinib-resistant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKBR3R |
| Perturbation |
Lapatinib |
| Concentration |
1uM |
| Relevant information |
Lapatinib resistant |
|
| 98 |
Lapatinib-resistant HER2-positive breast tumor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BT474J4 |
| Perturbation |
Lapatinib |
| Concentration |
1uM |
| Relevant information |
Acquired ... |
|
| 99 |
Systems analysis of adaptive responses to MAP ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
A375 |
| Perturbation |
Lapatinib |
| Concentration |
2uM |
|
| 100 |
Systems analysis of adaptive responses to MAP ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HT144 |
| Perturbation |
Lapatinib |
| Concentration |
2uM |
|
| 101 |
Systems analysis of adaptive responses to MAP ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMEL28 |
| Perturbation |
Lapatinib |
| Concentration |
2uM |
|
| 102 |
Systems analysis of adaptive responses to MAP ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMEL24 |
| Perturbation |
Lapatinib |
| Concentration |
2uM |
|
| 103 |
Anastrozole/Fulvestrant/Gefitinib neoadjuvant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
pre and post (3 wk) ... |
| Perturbation |
Gefitinib |
| Disease |
Breast Cancer |
|
| 104 |
Imatinib treatment of chronic myeloid leukemia ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
KU812, KCL-22, JURL-MK1 |
| Perturbation |
Imatinib |
| Disease |
Chronic myeloid leukemia |
|
| 105 |
Spectrum, clinical correlates and clinical ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Melanoma BRAF V600E |
| Perturbation |
Dabrafenib |
| Disease |
Melanoma |
|
| 106 |
Anti-proliferative effects of continued ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SKMel28 |
| Perturbation |
Dabrafenib 100nM |
|
| 107 |
Acute myeloid leukemia cell line Kasumi-1 ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
AML cell line |
| Perturbation |
Dasatinib |
| Disease |
Leukemia |
|
| 108 |
Imatinib mesylate effect on EOL-1 eosinophilic ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
EOL1 eosinophilic ... |
| Perturbation |
Imatinib 1 uM - 6 hrs |
| Disease |
Leukemia |
|
| 109 |
Imatinib mesylate effect on patient peripheral ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
PTCL/NOS cells |
| Perturbation |
Imatinib 1 uM - 6 hrs |
| Disease |
Peripheral T-cell ... |
|
| 110 |
Imatinib mesylate effect on bone marrow ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Bone marrow |
| Perturbation |
Imatinib |
| Disease |
Chronic myeloid leukemia |
|
| 111 |
Physiologic Hypoxia Promotes Maintenance of ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
CD34+ CML cells |
| Perturbation |
Imatinib 96 hrs - ... |
|
| 112 |
Physiologic Hypoxia Promotes Maintenance of ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
CD34+ CML cells |
| Perturbation |
Imatinib 24 hrs - ... |
|
| 113 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 2 hrs |
|
| 114 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 4 hrs |
|
| 115 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 6hrs |
|
| 116 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 9 hrs |
|
| 117 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 12 hrs |
|
| 118 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 24 hrs |
|
| 119 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 18hrs |
|
| 120 |
Detection of Treatment-Induced Changes in ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GISTT1 cells |
| Perturbation |
Imatinib 10 uM - 48 hrs |
|
| 121 |
Imatinib Treatment of GIST882
|
Homo sapiens
|
Homo sapiens |
| Cell |
GIST882 Cell line |
| Perturbation |
Imatinib 1 uM - 8 hrs |
|
| 122 |
Microarray study to understand acquired ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
ER3 nonsmall cell ... |
| Perturbation |
Erlotinib 1 uM - 12hrs |
|
| 123 |
Microarray study to understand acquired ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
T152 - non-small cell ... |
| Perturbation |
Erlotinib 1 uM - 12 hrs |
|
| 124 |
Role and function of Bach2 in BCR-ABL1 driven ...
|
Mus musculus
|
Mus musculus |
| Cell |
preB cells (BCR-ABL1 ... |
| Perturbation |
Imatinib 2uM - 16 hrs |
|
| 125 |
Imatinib and Nilotinib induced molecular ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
K562 cells |
| Perturbation |
Imatinib 0.5 uM - 24 hrs |
|
| 126 |
CD34+ Hematopoetic Stem cells (expressing ...
|
human
|
human |
| Cell |
CD34+ Hematopoetic ... |
| Perturbation |
Imatinib - 4 hrs |
|
| 127 |
Imatinib mesylate effect on EOL-1 eosinophilic ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
EOL1 - eosinophilic ... |
| Perturbation |
Imatinib 1 uM - 6 hrs |
|
| 128 |
Macrophages (tumor associated macrophages ...
|
mouse
|
mouse |
| Cell |
Macrophages (tumor ... |
| Perturbation |
Imatinib 600 mg/L |
|
| 129 |
Imatinib mesylate effect on EOL-1 eosinophilic ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
primary PTCL/NOS cells |
| Perturbation |
Imatinib 1 uM - 6 hrs |
|
| 130 |
Gene expression signature predictive of rapid ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
GIST Tumor |
| Perturbation |
Imatinib 600mg daily ... |
|
| 131 |
Bone marrow (CD34+ cells)_Imatinib
|
human
|
human |
| Cell |
Bone marrow (CD34+ cells) |
| Perturbation |
Imatinib |
|
| 132 |
CD34+ cells (Philadelphia +)_Imatinib _Chronic ...
|
human
|
human |
| Cell |
CD34+ cells ... |
| Perturbation |
Imatinib |
| Disease |
Chronic myelogenous ... |
|
| 133 |
Gene expression profiling in BCR/ABL ...
|
Mus musculus
|
Mus musculus |
| Cell |
HSCs (expressing ... |
| Perturbation |
Imatinib |
|
| 134 |
Bone marrow microenvironment effect on ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Bone marrow (CD34+ cells) |
| Perturbation |
Imatinib 5 uM - 96 hrs |
| Disease |
Chronic myeloid ... |
|
| 135 |
MET Amplified Gastric Cancer Cell Lines +/- ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
MKN45 Gastric Cancer ... |
| Perturbation |
Crizotinib 1 uM - 24 hrs |
|
| 136 |
MET Amplified Gastric Cancer Cell Lines +/- ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
SNU5 Gastric Cancer ... |
| Perturbation |
Crizotinib 1 uM - 24 hrs |
|
| 137 |
Expression data from EGFR WT or EGFR mutant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
NCIH23 |
| Perturbation |
Erlotinib 1 mM - 24 hrs |
|
| 138 |
Expression data from EGFR WT or EGFR mutant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
NCIH838 |
| Perturbation |
Erlotinib 1 mM - 24 hrs |
|
| 139 |
Expression data from EGFR WT or EGFR mutant ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
NCIH1648 |
| Perturbation |
Erlotinib 1 mM - 24 hrs |
|
| 140 |
DNA microarray analysis following ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
PC3 cells |
| Perturbation |
Gefitinib 60uM - 24 hrs |
|
| 141 |
Genome-wide analysis of gefitinib short-term ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HCC827 NSCLC cell line |
| Perturbation |
Gefitinib 0.5 uM - ... |
|
| 142 |
Lapatinib-resistant HER2-positive breast tumor ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
BT474 cells |
| Perturbation |
Lapatinib |
|
| 143 |
Oral ruxolinitib effect on alopecia areata ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
Scalp skin |
| Perturbation |
Ruxolinitib 12 weeks |
| Disease |
Alopecia |
|
| 144 |
Topical protein tyrosine kinase inhibitor ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Ruxolinitib 6 weeks |
|
| 145 |
Topical protein tyrosine kinase inhibitor ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Ruxolinitib 12 weeks |
|
| 146 |
Topical protein tyrosine kinase inhibitor ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Tofacitinib 6 weeks |
|
| 147 |
Topical protein tyrosine kinase inhibitor ...
|
Mus musculus
|
Mus musculus |
| Cell |
Skin |
| Perturbation |
Tofacitinib 12 weeks |
|
| 148 |
Genome-wide analysis of gefitinib short-term ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
PC9 NSCLC cell line |
| Perturbation |
Gefitinib 0.5 uM - ... |
|
| 149 |
Gene expression profiling of HDLM-2 Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
HDLM2 cells |
| Perturbation |
Givinostat 100 nM - ... |
|
| 150 |
Gene expression profiling of L-540 Hodgkin ...
|
Homo sapiens
|
Homo sapiens |
| Cell |
L540 cells |
| Perturbation |
Givinostat 100 nM - ... |
|